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Abstract 
Background: Irritable bowel syndrome (IBS) is a chronic functional disorder of the gastrointestinal 
system affecting a large number of people worldwide.  Whilst it has no attributable mortality, it 
has substantial impact on patients’ quality of life (QoL) and is associated with considerable 
healthcare resource use.   
 
Aim: To review the economic impact of IBS, firstly on the individual, secondly on health care 
systems internationally and thirdly to society. 
 
Methods: Appropriate databases were searched for relevant papers using the terms: Irritable Bowel 
Syndrome; IBS; irritable colon; functional bowel/colonic disease; economics; health care/service 
costs; health expenditure/resources; health care/service utilisation; productivity. 
 
Results: IBS impacts most substantially on patients’ work and social life. Reduction in QoL is such 
that on average patients would sacrifice between 10 and 15 years of their remaining life expectancy 
for an immediate cure. Between 15% and 43% of patients pay out-of-pocket for remedies. No 
studies quantify loss of earnings related to IBS.  Direct care costs are substantial, 48% of patients 
incur some costs in any year with annual international estimates per patient of: USA $742-$7547, 
UK £90-£316, France €567-€862, Canada $259, Germany €791, Norway NOK 2098 (€262) and 
Iran $92. Minimising extensive diagnostic investigations could generate savings and has been 
shown as not detrimental to patients.  Cost to industry internationally through absenteeism and 
presenteeism related to IBS is estimated between £400 and £900 per patient annually. 
 
Conclusions: IBS is associated with substantial costs to patients, health care systems and society. 
Considerable benefit could be obtained from effective interventions. 
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Introduction 
Irritable bowel syndrome (IBS) is a chronic functional disorder of the gastrointestinal system 
characterised by abdominal pain and altered bowel habit, with either predominantly diarrhoea, 
constipation or both. IBS has no attributable mortality1 but it is important due to the effect it has 
on quality of life (QoL)2,3 and the large number of people it effects, with a global prevalence of 
11%.4  With increased budgetary constraints on society and especially within health care systems 
it is important to consider the economic impact of such a prevalent condition.3 
 
The economic impact of any condition is comprised of the costs that are attached to it.  These 
costs fall into different domains so calculation will vary according to the perspective taken.5  Firstly 
there are costs incurred by the patient. These are the intangible cost to the individual in terms of 
reduced QoL,6 which includes reduced capacity to function in various roles, and direct financial 
cost through lost earnings and out-of-pocket expenses.7    Secondly, there is the direct cost of the 
health care, which can be considered in two ways.  One is to account for the explicit cost to the 
healthcare provider calculated from unit costs of resources and time used.  The other, more 
frequently used method, is to consider the price charged by the provider and incurred by a third 
party paying for healthcare provision, such as a government, insurer or health maintenance 
organisation (HMO).  These costs are derived from published tariff or reimbursement prices or 
charges.  These may be aggregate average prices for an average patient receiving that care and can 
include a mark-up to allow for profits, cost-sharing or to cover losses in other areas depending on 
the healthcare system.8  Costs from a third party payer perspective are those most easily available 
and most widely analysed.3  Finally there is the cost to society in terms of indirect cost from reduced 
productivity in the workplace, both from the individual with the condition but also due to time 
lost due to spill over effects on others in the patients’ family.  Indeed the cost to other family 
members may also include reduction in their QoL.5  Costs to society will also include those costs 
to sectors outside health, including education and social security.9 
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This review aims to assess the economic impact of IBS on the individual, healthcare system and 
to society and establishes common themes across different healthcare systems.  For individuals, 
we describe how QoL is affected and quantify their out of pocket expenses and loss of earnings.  
We will outline the healthcare utilisation and direct costs to health care systems in different 
countries, specifically focussing on health care attendance, investigations and prescribed drugs.  
Finally, we will discuss absenteeism, presenteeism, industry and carer costs which all contribute to 
the wider costs to society of IBS.  This synthesis of the available research evidence will outline the 
magnitude of the potential benefit that effective interventions in IBS could make.   
 
Search strategy 
This is a narrative review, but to ensure it reflects current literature a search was conducted in 
January 2014 of the following databases: NHS Economic Evaluation Database (NHS EED), 
Database of Abstracts and Reviews of Effects (DARE), International Agencies for Health 
Technology Assessment database (INAHTA), Cochrane Review, EMBASE and Medline.   The 
search terms used were: (Irritable Bowel Syndrome OR IBS OR irritable colon OR functional 
bowel disease OR functional colonic diseases) AND (economic models OR economic* OR cost* 
OR health care costs OR health service costs OR health expenditure OR health resources OR 
health care utilisation OR health service utilisation OR productivity).  These papers were limited 
to English language and abstracts were reviewed for relevance.  References were checked to ensure 
all potentially relevant papers were retrieved. Grey literature sources were not searched. 
 
Cost to the patient 
Measuring quality of life and generating utility values 
The emotional, social and physical dimensions of a person's life are captured through measurement 
of QoL.  Changes in these domains due to an illness may be assessed either using a generic 
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instrument that can be generalised to all conditions or using an instrument specific to the illness 
of interest.10  To capture the impact of QoL reduction due to IBS in economic evaluation, these 
measurements need to be converted to utility values.  The conversion of QoL measures into 
utilities describes quantitatively an individuals’ preference for a particular health state under 
conditions of uncertainty,11 an essential theoretical principle underpinning health economics.5,12  
People are asked about their preferences for different health states and to trade time from their 
future life expectancy to avoid that state.13  Utility values are between 0 and 1, where 1 is equivalent 
to perfect health and 0 is death (negative scores do exist where patients feel a health state is worse 
than being dead) and these scores can then act as weights for quality in the calculation of quality 
adjusted life years.11  
 
The Euroqol-5 Dimensions (EQ5D) questionnaire has had all potential QoL outcome scores it 
may generate mapped to country specific utility values which allows comparison of utility across 
diseases and countries.13  Thus it supports economic analysis in a way that a disease specific 
instrument may not. EQ5D has been shown to be valid in IBS, it is sensitive to change in disease 
captured on disease specific instruments11 and had good longitudinal validity.14 A change on the 
utility scale of 0.03 is the minimum for a clinically important difference in IBS.14 
 
Quality of life and utility in IBS 
IBS causes significant reductions in all dimensions of QoL.2  In the USA, 68% of survey 
respondents reported missing 10 activities or social events on average over a 3 month period due 
to their IBS, equivalent to one activity per week.15  When questioned, the majority of IBS patients 
responding to a newspaper advert in the UK reported feeling angry about having IBS and fed up.16  
Over two thirds of respondents reported at least some pain and half experienced at least moderate 
anxiety and depression.16 Due to the nature of their selection, these patients may not be 
representative of all people with IBS, but similar findings are seen across Europe and North 
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America.11,15,17 Compared to colleagues without IBS, the factor most significant in lowering QoL 
for workers with IBS in the US is reduction in their capacity to fulfil their physical roles.2  The 
same was found in European patients with IBS from primary and secondary care, who also 
expressed lower perception of their own health than people without IBS.11  The other factors 
substantially reducing their QoL were the impact IBS had on their work, social life and ability to 
travel.11   Bowel symptom severity and psychological symptom severity have the most significant 
effect on reducing QoL in IBS patients, and if present together reduce QoL further in an additive 
manner.18 
 
Studies across Europe and North America show reasonably consistent reduction in overall mean 
EQ5D scores compared to the general population of around 0.14-0.22.11,19  The overall mean 
values vary between 0.62 to 0.75.11,14,17,19 This compares to utility values of between 0.77 and 0.92 
in patients with inflammatory bowel disease,20,21 0.82 to 0.84 for patients with coeliac disease22 and 
0.76 to 0.85 in patients diagnosed with potentially treatable colorectal cancer.23  In IBS, a 0.2 point 
decrease in health utility on this score has been demonstrated between those with mild to moderate 
symptoms and those with severe symptoms.19  Mean baseline utility of between 0.62 and 0.75 is 
considered equivalent to a patient of 35 with an expected 40 years of life remaining being willing 
to sacrifice between ten years (if 0.75) and 15 years (if 0.62) for a permanent and immediate cure 
for their IBS.14  No significant difference in overall QoL or in the domains affected has been 
reported between patients younger than 50 years and those who are older.24  IBS symptoms 
fluctuate over time, and it has been shown that without any intervention there is no real change in 
QoL in patients in the community or attending primary care over three months.14,25  Longer time 
intervals have not been assessed. 
 
Out of pocket costs 
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Few studies have considered the direct out of pocket cost to patients with IBS.  The majority of 
preparations used to control symptoms in IBS are available over-the-counter and many non-drug 
treatment options for IBS are available without the need to access health care systems (for example 
acupuncture), consequently community studies are most likely to reflect the true proportion of 
patients with IBS who take medication or access these services.8  Estimates suggest between 15%26 
and 43%17 of patients take over the counter remedies with almost two thirds of them buying 
laxatives, over a third analgesics and 32% buying more than three medications.17  The cost to the 
patient of acquiring these remedies has not been assessed.  Along with medication costs, 
transportation to and from clinic appointments have not been considered.  Similarly, some patients 
will choose to pay for alternative therapies or to see a physician or surgeon privately regarding 
their IBS and these costs, too, have not been measured.   
 
Loss of earnings  
Time off work, the need to reduce hours and changing roles due to IBS symptoms have all been 
reported,25,26 with as many as 12% of patients stopping work all together due to IBS.26 Evaluation 
of these costs have been considered from the perspective of the employer, however and not 
through loss of earnings.   
 
The intangible cost to the patient from reduced QoL is frequently measured and considered within 
economic evaluation.  These indirect costs incurred by the patient, however, are not captured in 
third-party cost estimates and rarely fully assessed in societal evaluations.8 
 
Cost to the provider or a third-party payer 
Calculating direct costs 
To calculate the direct healthcare costs of any condition, healthcare utilisation of patients with that 
condition must be measured. This can be done using community questionnaires, where patients 
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are asked directly about their patterns of healthcare use, from primary care or secondary care 
records or from administrative databases.  Once the amount of healthcare utilization has been 
assessed, the cost of this care can then be calculated.  As described in the introduction, direct 
health care costs can be calculated from the perspective of the provider or that of the payer. All 
of the studies of healthcare costs in IBS consider them from the point of view of the payer, either 
a national health service, HMO or third party payer.  The difference between HMO costing and 
third party payer costing is that the HMO, like national health services uses tariff rates whilst third 
party payers use charges levied.   
 
Differences in how healthcare systems are organised and financed are likely to cause some variation 
in the number of people choosing to consult with IBS symptoms and who they consult.  Some 
healthcare providers, such as national health services and health maintenance organisations 
(HMO), may insist on consulting particular healthcare professionals with strict guidelines for 
further management once they present, whilst non-HMO insurance providers may allow greater 
freedom in whom a patient consults and the investigations and treatment they receive.  Similarly 
as suggested above, some patients may choose to pay out of their own pocket to see a physician 
and the price differentiation may affect who they choose to consult and how much further 
healthcare they utilize.   Despite these variations the trends in utilisation described above remain 
broadly similar. 
 
Primary care 
In the USA 25-49% of IBS patients consult a primary care physician in a year, with an average of 
2-3 visits per year.27–29  This is a similar rate to that seen in people with asthma or migrane.7 Just 
under half of these consultations are directly related to IBS symptoms, with abdominal pain the 
predominant feature associated with consultation.29  When questioned, over half of those patients 
not presenting for the first time said that they were re-attending because previous treatment was 
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unsatisfactory.28  No significant variation in attendance has been demonstrated by IBS sub-type.28 
Overall, from a community based study in the USA, when compared to people without  IBS, over 
the course of one year 17% more of the group with IBS will visit a physician.29  On average in the 
UK patients with IBS will have slightly more than one additional attendance at primary care over 
a year than people without IBS.25 There is scant data on consultation over longer periods, but one 
UK study shows that among those newly developing IBS over a ten year period, the median 
number of primary care consultations for IBS was only 1 with the maximum being 14.30  These 
figures from the USA and the UK are somewhat lower than reported in Germany, where medical 
records showed that IBS patients had an average of 9 primary care visits per year.31 Primary care 
visits account for up to 30% of total direct healthcare costs for patients with IBS.6,31–33 
 
Secondary care 
In the USA, during the year that patients are diagnosed with IBS, 19% will consult secondary 
care.27  A study of primary care in the UK found that 30% of IBS patients were referred to 
secondary care where two thirds of them saw a physician and a third saw surgeons.34  Patients who 
deny stress is associated with their symptoms,34 men, those with diarrhoea, people taking 
medication and those seeking alternative therapy are all more likely to attend secondary care.16  
Likelihood of being referred to secondary care falls by 6% every month after initial diagnosis.16  A 
survey of gastroenterologists in the North of England reported that these referrals accounted for 
36% of all new patients and that on average each patient would have two visits.6 
 
Emergency care 
Few people require emergency care for IBS and it accounts for only a small number of hospital 
admissions.  The proportion of patients with IBS receiving emergency care is broadly similar in 
Europe and North America, ranging from 2-5%.17,27,31  IBS patients who report moderate or severe 
abdominal pain are more likely to seek emergency care (p<0.05).35  Admission to hospital for IBS 
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occurs in 0.5-6.5%, with lower rates in North America than Europe6,17,27,31 Despite this low rate, 
the significant cost of inpatient care means it accounts for 25-30% of total healthcare cost for 
IBS.6,31 
 
Surgery 
Rates for abdominal surgery are also higher in those with IBS than in those without, with IBS 
patients receiving twice as many  appendectomies36,37  or hysterectomies36 and  2-336,38 times as 
many cholecystectomies.  About a quarter of patients with IBS have gynaecological surgery and a 
third have an appendectomy or cholycystectomy.39.   
 
Prescriptions 
Whilst the cost of medication obtained over-the-counter is borne by the patient, prescription 
medications form healthcare costs to the provider, health service or the third party payer.  Costs 
of medications received on prescription are more easily estimated than those obtained without 
because prescription data are recorded on the insurance claims or care providers’ database, 
although these are not all collected by the patient. Between 33% and 91% of patients with IBS 
receive a prescription for medication in any year17,31,39 and on average, IBS patients will receive 3-
7 prescriptions per year for medication to treat IBS symptoms.6,27,31  Compared to people without 
IBS this represents 2-3 more prescriptions over a year.25  In the UK the most frequently prescribed 
medications are antispasmodics (30%) and laxatives (25%).6  Anti-diarrhoea agents are just 6% and 
antidepressants 3%.6 
 
Investigations 
In the USA during the year of diagnosis with IBS patients will have an average of six blood tests,27 
one outpatient procedure27 and one radiological procedure specifically related to their IBS.   
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In Europe 63-84% of IBS patients receive a diagnostic procedure17,31,34  with half having abdominal 
ultrasound scans and over a third undergoing colonoscopy.17  Nearly 25% of colonoscopies in 
patients aged under 50 in the USA have previously been reported as being performed to investigate 
IBS,40  despite evidence that colonoscopy in IBS has a low diagnostic yield41 and is unlikely to 
provide any reassurance to the patient.42  The USA may have different rates of colonoscopy to 
other countries due to a higher level of patient demand led investigations and incentives to provide 
investigations due to the reimbursement system.43  
 
The amount a patient is investigated for their IBS symptoms, and the subsequent cost, will depend 
on whether the physician is confident in making a positive clinical diagnosis.44  In the USA 72% 
of physicians treat IBS as a diagnosis of exclusion44 and these physicians were found to order 
between 1 and 2 additional tests on average compared to those confident in making a positive 
clinical diagnosis, costing an additional $364 per patient.44  A Danish study of primary care 
compared a diagnosis of exclusion shown to be frequently used in Western countries44,45 with a 
positive diagnosis following clinical guidelines.46,47 The total cost of the minimum number of 
investigations undertaken for a diagnosis of exclusion (coeliac, thyroid and liver screen, full blood 
count and inflammatory markers and lactase gene test, stool analysis and sigmoidoscopy) was 
$913.59 compared to $50.11 for clinical diagnosis supported by normal full blood count and 
inflammatory markers.45   There was no significant difference in change in symptoms, severity or 
satisfaction between those receiving the minimal or more extensive investigations, either at one 
month or one year follow-up.  During the following year neither group of patients had significantly 
different utilisation of healthcare resources, with the median total cost of care for those diagnosed 
by exclusion being $127/patient compared to $112/patient for those diagnosed positively 
(p=0.70).45  After one year the additional investigations in those diagnosed by exclusion had 
identified organic disease in 10% of patients (10 lactose intolerance, 1 rectal adenoma and 1 
parasitosis), none of the patients diagnosed using a positive clinical strategy had received further 
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investigation for ongoing or new symptoms.45  These studies show that adhering to the current 
guidelines for diagnosing IBS from clinical findings with a normal full blood count and 
inflammatory markers in the absence of alarm features confers a significant cost saving without 
significant detriment to the patient.44,45   
 
Overall costs 
Between a third and a half of people within the community who have symptoms that would be 
diagnostic of IBS will seek medical advice1,37,48,49 (range from 10%37 to 70%50) and  those who do 
consult a physician tend to consult regularly.   In any year, 48% of patients diagnosed with IBS will 
incur some direct medical cost from gastroenterological related healthcare51 and when non-
gastrointestinal care is also considered, this increases to 88-94%.32,48   
 
Variations in estimates of overall direct healthcare cost are considerable (table 1).  Studies from 
the USA estimate the annual cost per patient with IBS between $74232 and $7547,52 with a projected 
annual cost for the nation of $1353million.53  Estimates of annual costs per patient are more 
conservative elsewhere, with UK estimates between £906 and £316,25 France €567 to €862,54 
Canada $259,33 Germany €79131 and Iran $92.55 The mean cost for Norwegian IBS patients directly 
related to their IBS over 6 months is NOK 1049 (€131), but costs for comorbid conditions in the 
same patients is 14 times greater (NOK 14856 [€1857]).56  National annual projections for the cost 
to a country of treating patients with IBS range from £45.6-£200million in the UK,6,25 €3.1-
4.1billion in Germany31 and $2.94billion in Iran.  There is significant heterogeneity between these 
studies (table 1).  The most important differences are between the year that the costs relate to, 
whether costs were those felt to be directly related to IBS care or all care, cost perspective, the 
population, the source of utilisation and cost data and whether mean or median costs were used 
as summary measures.  This heterogeneity makes the reported estimates barely comparable but 
they do show that there is a substantial direct healthcare cost burden attributable to IBS.  Health 
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care costs are higher in patients with IBS than those without IBS in all domains of health care 
utilisation.25,35  It is not surprising that patients with IBS have higher healthcare costs than people 
without IBS in the year that they are diagnosed, but this increased cost persists up to three years 
after diagnosis.27,57 Of the excess healthcare costs, 66-80% are not attributable to gastrointestinal 
complaints.27 The increased utilisation of healthcare resources for non-gastrointestinal issues and 
the increased costs attached may reflect significant levels of comorbidity in patients with IBS,56 
including the burden of multiple functional conditions which tend to cluster in these individuals.58–
60 
 
The studies described here all calculate the cost per year for patients with IBS from whichever 
perspective is adopted rather than the cost of IBS per patient over a lifetime.  Despite this, the  
evidence that direct costs for patients with IBS remain increased three years following diagnosis27,57 
and are significantly higher than for people without IBS for non-gastrointestinal care as well as 
gastrointestinal care,6,25,27,32,35,61 would suggest that the cost of IBS over a patient’s lifetime are 
considerable. 
 
Societal costs 
Taking a societal perspective to calculating the cost of an illness aims to capture the impact of that 
condition on the welfare of the whole of society, not just the individuals affected and the healthcare 
sector.   The cost a condition places on society outside of the direct health care costs can fall in 
other sectors such as education, social services and industry.  The effects on industry are commonly 
from loss of productivity of individuals within the workplace, either through absenteeism or 
through reduced functioning whist at work, presenteeism.  Productivity costs are especially 
important in conditions such as IBS that have a higher burden of morbidity than mortality.8 
 
Absenteeism 
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Patients with IBS are twice as likely to take time off work as colleagues.25  In Europe, between 
15% and 50% of people with IBS require time off work due to their IBS symptoms.25,26,45,54 Far 
fewer, just 6% of Canadian patients report taking time off work due to IBS.17  One UK study 
found that whilst a greater proportion of people with IBS took time off work than those without 
IBS, on average the amount of time they took off was not statistically significantly different to 
those without IBS.25  A larger study asking patients in a number of European countries, however, 
reported that patients with IBS took almost twice as many days off work over a year.37 Around a 
quarter of patients take more than 3 days off due to their IBS symptoms annually,26,45 and 7% take 
more than two weeks.26  In Europe and the USA patients with IBS take on average 3 to 4 extra 
days off work per year compared to colleagues without IBS.2,37 There is a statistically significant 
(p<0.05) association between the severity of IBS symptoms reported by a patient and the need to 
take time off work, with those experiencing severe symptoms requiring an average of one day off 
per month.62  Variation in employment law and sickness benefit provision may account for 
differences between rates in different countries and variation in sick pay provision or being self-
employed may contribute to differences between individuals.  Patients who respond to self-
reported questionnaires, which make up the majority of these studies, are likely to be a biased 
sample, with one study reporting that over half of the respondents had daily symptoms,26 
suggesting they may be more likely to take time off work.   
 
Presenteeism 
Presenteeism is assessed by asking people how much of the time while at work they feel they were 
not performing to the best of their ability through either a reduction in the amount or kind of 
work they could do, accomplishing less than anticipated or being unable to work as carefully as 
usual due to symptoms of IBS during a specified period.19,63  This is a more subjective measure 
than absenteeism and estimates of time lost through presenteeism vary widely, with patients 
reporting between 2%55 and 32%17,63 of their working week lost due to IBS symptoms. Severity of 
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IBS symptoms significantly increases presenteeism (p<0.001)63 and those with mild symptoms lose 
7% less time than those with moderate or severe symptoms.19 
 
Overall cost to industry 
Assessing loss of productivity by combining measures of absenteeism and presenteeism due to 
IBS over a year and multiplying this by the average wage of the individuals provides an estimate 
of the annual cost to companies.  One US national company calculated costs due to absenteeism 
in IBS patients in 1998 as $901 per patient, 70% more than those without IBS.64  Another in 2005 
calculated their productivity loss attributable to IBS to be $7737 per patient (95% CI &7332-8143).2  
By using the average population earnings the annual cost to society through productivity loss 
attributable to IBS can be generated. In Denmark the median annual cost is between $1,360 and 
$1,508 per patient from absenteeism.45  Through absenteeism and presenteeism combined, the loss 
per IBS patient is estimated to be $748 in Canada,33 €995 in Germany31 and $812 in Iran.55 
 
Carer burden 
Most papers considering societal costs fail to consider the cost to those caring for or living with 
people who have IBS.  One study has assessed 152 partners of patients with IBS, who had been 
together for an average duration of 20 years and compared their feelings of satisfaction and burden 
within the relationship to the partners of healthy controls.65 Partners of patients with IBS reported 
feeling significantly more strained, distressed and under a greater burden than those of healthy 
controls.  The level of burden expressed was reported to be comparable to partners of people with 
dementia and greater than the carers of terminal cancer patients.65  This shows that there is likely 
to be an important impact on the QoL of partners.65   
 
Summary 
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IBS is a chronic condition that represents a significant burden to individuals, healthcare systems 
and society.  QoL is substantially reduced for patients with IBS in all domains, which limits their 
daily activities.  Patients with IBS utilise more healthcare resources than those without IBS for 
gastrointestinal symptoms and also for non-gastrointestinal related care which persists well beyond 
the first year following diagnosis.  Patients with IBS are more likely to require time off work than 
people without IBS and report that when they are at work their symptoms considerably affect their 
productivity and ability to optimally perform their job.  This loss of productivity is costly to the 
workplace and the employer and to society as a whole not only via the effects on the individual 
with IBS but also those caring for them.     There is some evidence of the financial cost to patients 
in terms of out of pocket payments for over the counter medication, but this is limited and there 
is no data on cost to the patient of other therapies or costs related to transport and attending clinic 
appointments. 
 
International guidelines emphasise positive clinical diagnosis for IBS and management within 
primary care.  The findings that few patients investigated extensively for IBS symptoms have 
organic disease and that colonoscopies in these individuals almost always find no pathology would 
suggest that some of the extensive investigations and associated costs in patients with IBS are 
unnecessary and could indicate an area for cost reduction.  There has also been some assessment 
of where costs fall within healthcare, with utilisation and costs being grouped usually into primary 
care, inpatient care, outpatient care, emergency care, prescriptions and procedures/radiology.  
Greater division of these costs, for instance by specialty and procedure type may provide targets 
for improved service provision or cost savings.  Likewise, greater consideration of non-drug 
interventions is needed.  Some such interventions have been shown to be effective in IBS 
management66 and there is currently no evidence of how many people access them, who pays for 
this care and how much it costs.  From a wider societal perspective, there are no studies that 
consider the impact IBS may have on education or other sectors outside of health, such as social 
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security.  The benefit of filling these gaps in the literature would be to better inform future 
economic modelling for healthcare cost saving and resource allocation and to capture the full 
potential cost effectiveness of new interventions to the individual, the healthcare system and 
society. 
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Author 
(publication 
year) 
Country Setting Population Perspective Resources included Currency 
(cost 
year) 
Outcome 
Talley 
(1995)32 
USA Community 536 responders to 
a postal 
questionnaire sent 
to randomly 
selected people 
from a 
computerised 
database of 
healthcare charges 
from one county 
(calculated to 
include 95% of 
county’s 
population) 
Third party 
payer 
From computerised 
database of healthcare 
utilization and billing:  
primary and secondary 
care costs, out-patient 
costs assessed separately; 
laboratory and radiology 
costs. 
US $ 
(1992) 
Overall median annual 
costs per patient = $742 
and $893 excluding those 
with zero cost ($429 and 
$659 for those without 
IBS) 
 
Extrapolation to US white 
population annual cost 
$8billion 
Wells 
(1997)6 
UK National 
Health Service 
No one population 
of patients – 
aggregate 
utilisation and 
costs generated 
from general 
practice database 
and physician 
survey data 
National 
Health 
Service 
** only costs assumed to 
be directly related to IBS  
 
General practice survey: 
primary care 
consultations 
 
General practice 
database: prescriptions 
 
Gastroenterologist 
survey: out-patient 
attendance, inpatient 
care 
UK £ 
(1995) 
Mean total annual cost 
per patient = £90 
 
Extrapolated annual costs 
for hospital sector = 
£20million 
 
Extrapolated annual UK  
population cost = 
£45.6million (0.1% total 
NHS annual expenditure) 
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Bentkover 
(1999)33 
Canada Primary and 
secondary 
care 
120 medical 
records of IBS 
patients followed 
up for 5 years in 
primary care and 2 
years in secondary 
care 
Societal ** only costs assumed to 
be directly related to IBS  
 
From medical records: All 
physician visits, 
Diagnostic tests, 
prescriptions, emergency 
visits 
 
Modelled calculations: 
costs of presenteeism 
and absenteeism 
Canadian 
$ (1996) 
Modelled mean annual 
cost per patient: 
 
Direct medical costs = 
$258.82 
 
Indirect (work place) = 
$748.16 
 
Overall societal cost = 
$1006.98 
Ricci 
(2000)52 
USA Administrative 
claims 
database 
2770 patients from 
an administrative 
database of 
medical and 
pharmacy claims 
with first diagnostic 
record of IBS 
between 1st July 
1996-30th 
September 1997 
Third party 
payer 
Claims database: 
physician visits, inpatient 
care, outpatient care, 
hospitalisation, 
medication, 
US $ 
(1997) 
Mean annual cost per 
patient = $7547 
Levy 
(2001)27 
USA Health 
maintenance 
organisation  
3153 incident IBS 
patients (enrolled 
patients with first 
diagnostic code for 
IBS in 1994 or 
1995) 
Managed 
care 
From records of charges 
to insurer: Primary care 
visits, specialty visits, 
mental health visits, 
medications, laboratory 
tests, radiology, 
hospitalisation, 
emergency visits, GI and 
non-GI care 
US $ 
(1995) 
Total mean annual health 
care costs per patient = 
$3786 
($1130 more than non-
IBS controls) 
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Creed  
(2001)67 
UK Secondary 
care 
257 patients with 
severe refractory 
IBS attending 7 GI 
out-patient clinics 
in Northern 
England enrolled 
for a trial of 
psychological 
therapy.  Costs 
calculated for the 
year before trial 
entry 
National 
Health 
Service 
From primary and 
secondary care records: 
in-patient days, out-
patient  and day case 
attendance, A&E visits, 
GP visits, home visits, 
Nurse consultations, 
domiciliary care, day 
rehabilitation centre 
attendance, alternative 
therapy use, prescriptions 
Patient questionnaire: 
travel, non-prescribed 
medication, additional 
household expenditure 
including child and 
personal care, loss of 
wages and productivity 
loss. 
Costs 
calculated 
in UK £ 
and 
converted 
to US $ 
Mean direct annual 
health care costs: $1743 
 
Annual cost per patient 
due to lost productivity: 
$334.50 
Akehurst 
(2002)25 
UK Primary care  
 
161 IBS patients 
diagnosed  using  
ROME I criteria; 
213 age sex and 
practice matched 
controls 
National 
Health 
Service 
 
From primary care 
records: primary care 
appointment; home 
visits; prescriptions; 
hospital outpatient by 
specialty; emergency 
attendances; inpatient 
episodes; time off work 
UK £ 
(1997/98) 
Mean annual cost per 
patient = £316.20    
(£123/year more than 
controls)  
 
IBS patients average 1.5 
days off work/month, not 
costed 
 
Scaled up annual 
population direct cost  
= £200million 
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Sandler 
(2002)53 
USA US population National survey 
data for healthcare 
utilisation 
 
Societal National survey 
databases: inpatient care, 
outpatient visits, 
emergency care, 
procedures, prescriptions 
Indirect costs calculated 
from previously published 
ratio of direct to indirect 
costs in gastroenterology  
US $ 
(1998) 
 Annual total US 
population societal cost = 
$1353million 
Muller-
Lissner  
(2002)31 
Germany Primary and 
secondary 
care 
200 randomly 
selected IBS 
patients with data 
extracted from 
medical records via 
structured 
interview with 
physician 
Third party 
payer and  
Societal 
From medical records 
(56% primary care; 44% 
secondary care): 
diagnostic procedures, 
outpatients by specialty, 
prescriptions, other 
therapy, hospitalisation, 
days off work as recorded 
in the medical records 
€  
(1999) 
Total annual direct 
healthcare costs = 
€791.48 
 
Total annual societal cost 
= €994.97 
 
Scaled up total annual 
population cost (societal 
perspective)  
= € 3.1-4.1 billion 
Patel 
(2002)61 
USA Health 
Maintenance 
Organisation  
501 patients with 
first IBS diagnostic 
code in 1998  
Managed 
care* 
From insurance claims 
data: emergency care, 
inpatient care, out-
patient visits, 
prescriptions, 
procedures, laboratory 
tests) 
US $ 
(1998) 
Annual median total cost 
per patient  
= $2237-2504 
($355-843 more than 
controls) 
Leong 
(2003)64 
USA Administrative 
claims 
database  
Employees and 
retirees of a 
national company 
and their spouses 
and dependents 
Third party 
payer 
Claims database 
reimbursements: 
physician visits, inpatient 
care, outpatient care, 
hospitalisation, 
medication, disability 
US $ 
(1998) 
Annual overall total cost 
per patient = $4527 
($1251 more than 
controls) 
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with diagnoses of 
IBS recorded 
claims and cost of time 
lost from sporadic sick 
days and time at medical 
appointments 
Annual cost of 
absenteeism $901 ($373 
more than controls) 
Longstreth 
(2003)35 
USA Health 
Maintenance 
Organisation 
578  patients  who 
has had a 
sigmoidoscopy in 
2000 with ROME I 
defined IBS 
following postal 
survey (controls 
had sigmoidoscopy 
but not IBS on 
questionnaire) 
Managed 
care* 
From insurance claims 
database: outpatient 
visits by specialty, 
inpatient care, 
prescriptions, radiology, 
laboratory tests. 
US $ 
(2000) 
Mean overall total annual 
costs per patient = 
$3729.04 
 
(adjusted: 51% higher 
than controls) 
Le Pen 
(2004)54 
France French 
population 
253 patients 
identified through 
a population survey 
Third party 
payer and 
society 
Questionnaires and 
patient interviews:  
physician visits, inpatient 
care, outpatient care, 
hospitalisation, 
medication, 
investigations, 
absenteeism 
Euro 
(1999) 
Average overall monthly 
direct medical costs per 
patient = €47.30 (95% CI 
36.90-57.70) 
Spiegel 
(2005)51 
USA Secondary 
care 
1410 consecutive 
IBS patients to 
gastrointestinal 
outpatient clinics 
Third party 
payer 
**only gastrointestinal 
costs considered 
 
Patient completed 
questionnaire:  
outpatient visit, 
procedures, radiology, 
surgery 
US $ 
(2004) 
Mean  total annual 
gastrointestinal costs per 
patient = $3280.80 
Roshandel  
(2007)55 
Iran Secondary 
care 
Patients with 
ROME II defined 
IBS attending a 
Societal **only gastrointestinal 
costs considered 
 
US $ 
(2005) 
Annual mean cost per 
patient: 
 
28 
 
gastroenterology 
outpatient clinic 
(number with IBS 
not reported) 
Patient interview: 
primary care visits, 
outpatient attendance, 
inpatient care, laboratory 
tests, radiology, 
prescriptions, days off 
work due to IBS, days 
working at 30% less than 
optimal function 
direct cost = $92.04 
 
productivity loss = 
$811.85 
 
overall societal cost = 
$903.89 
 
Extrapolated population 
annual societal cost = 
$2.94 billion 
Nyrop 
(2007)68 
USA Healthcare 
Maintenance 
Organisation 
588 patients with 
ROME II defined 
IBS through patient 
questionnaire from 
stratified sampling 
of the health 
maintenance 
organisation 
database 
Managed 
care* and 
assessment 
of out-of-
pocket 
treatment 
costs 
Administrative claims: 
primary care vists, out-
patient visit, in-patient 
care, emergency care, 
mental health service 
use, radiology, 
laboratory, prescriptions, 
other out-patient related 
costs.  Gastrointestinal 
and non-gastrointestinal 
costs stratified 
 
Patient questionnaire: 
non-prescription 
medication, alternative 
treatments 
US $ 
(2002) 
Mean total annual direct 
costs per patient = $5049 
 
Mean annual out-of 
pocket costs per patient = 
$406 
Johansson 
(2010)56 
Norway Primary care 208 patients 
identified with IBS 
through 
questionnaires sent 
to primary care 
patients 
National 
health 
service 
Patient questionnaire and 
electronic medical 
records: investigations, 
consultations (primary 
and secondary care and 
alternative therapists), 
NOK 
(2001 - in 
2001 NOK 
1 = €8) 
Mean overall 6 months 
IBS related costs = NOK 
1049 
Mean overall 6 monthly 
total costs (IBS and non-
IBS care) = NOK 15905  
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Table 1: Description and comparison of papers calculating the economic burden of IBS 
 
hospitalisation, 
prescribed and non-
prescribed medication, 
days of sick leave 
 
(median 6 monthly 
overall IBS related costs = 
NOK 0 [0-60468]) 
Begtrup 
(2013)45 
Denmark Primary care 302 patients aged 
18-50 fulfilling 
ROME III criteria 
for IBS 
National 
Health 
Service and 
societal 
analysis 
 
 
Monthly patient 
questionnaires: GP 
consultations; specialist 
consultations; emergency 
visits; Investigations 
US$ 
(2012) 
Median total direct costs 
over one year following 
diagnosis:  
Diagnosed by exclusion = 
$127/patient 
Positive clinical diagnosis 
= $112/patient 
Overall median  total 
annual  societal cost per 
patient diagnosed by 
exclusion = $1614  
positive diagnosis = 
$1776 
